¼¼°èÀÇ ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2033³â)
Peripheral Drug Eluting Balloon Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå¿¡ °üÇÑ Á¾ÇÕÀûÁ¶»ç ¸®Æ÷Æ®¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤µ¿Ç⡤½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤°úÁ¦¸¦ Æ÷ÇÔÇÑ Áß¿ä ½ÃÀå ¿ªÇÐÀ» öÀúÈ÷ Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ ÀλçÀÌÆ®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå ±Ô¸ð(2024³â) : 9¾ï 4,860¸¸ ´Þ·¯
½ÃÀå ¿¹Ãø(2033³â) : 19¾ï 5,050¸¸ ´Þ·¯
¼¼°è ½ÃÀå ¼ºÀå·ü(CAGR 2024-2033³â) : 8.3%
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå - Á¶»ç ¹üÀ§
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼±Àº ¾à¹°À» µ¿¸Æº®¿¡ Á÷Á¢ Àü´ÞÇÏ¿© ÀçÇùÂøÀ» ¾ïÁ¦Çϰí Ç÷·ù¸¦ °³¼±ÇÔÀ¸·Î½á ¸»Ãʵ¿¸ÆÁúȯ(PAD) Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ Ç³¼±Àº º´¿ø, Ŭ¸®´Ð, ¿Ü·¡ ȯÀÚ ¼¾ÅÍ µî ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ´Ù¾çÇÑ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ´Ù¾çÇÑ ¾à¹° Á¦Çü°ú dz¼± Å©±â¸¦ Á¦°øÇϸç, PADÀÇ À¯º´·ü Áõ°¡, dz¼± ±â¼úÀÇ ¹ßÀü, ÃÖ¼Ò Ä§½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ :
¼¼°è ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀåÀº Àü ¼¼°è¿¡¼ ¼ö¹é¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â PADÀÇ ¹ßº´·ü Áõ°¡¿Í °°Àº ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÈûÀÔ¾î ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ¾à¹°Àü´Þ°ú ÀçÇùÂø·üÀ» ³·Ãß´Â È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ¾àÁ¦¿ëÃâ dz¼±ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾à¹° ÄÚÆÃ ¹× Àü´Þ ¸ÞÄ¿´ÏÁòÀ» °³¼±ÇÑ Â÷¼¼´ë dz¼± °³¹ß µî ±â¼ú ¹ßÀüÀº Ä¡·á È¿°ú¿Í ȯÀÚ ¿¹Èĸ¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÃÖ¼Òħ½ÀÀû ¼ö¼úÀÇ Ã¤Åà Áõ°¡¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥Àº ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
¼ºÀå °¡´É¼ºÀÌ ³ôÀº ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀåÀº ±ÔÁ¦ Áؼö, ³ôÀº ºñ¿ë, ½ÅÈï ½ÃÀå¿¡¼ÀÇ ³·Àº ÀÎÁöµµ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¾àÁ¦¿ëÃâ dz¼±ÀÇ ½ÂÀÎ ¹× »ç¿ë¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦´Â Á¦Á¶¾÷ü¿¡ Å« ±ÔÁ¦ Áؼö ºÎ´ãÀ» ¾È°ÜÁÖ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯È÷ ÀÇ·á ¿¹»êÀÌ Á¦ÇÑµÈ Áö¿ª¿¡¼´Â ¾àÁ¦¿ëÃâ dz¼± ¹× °ü·Ã ½Ã¼úÀÇ ³ôÀº ºñ¿ëµµ º¸±Þ¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÈï ±¹°¡¿¡¼´Â PAD¿Í »ç¿ë °¡´ÉÇÑ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ÀνÄÀÌ ³·´Ù´Â Á¡µµ ½ÃÀå ħÅõ¿¡ °É¸²µ¹·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀåÀº ±â¼ú Çõ½Å, Àα¸ Áõ°¡, ÇコÄɾî ÀÎÇÁ¶ó È®´ë°¡ Å« ¼ºÀå ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÷´Ü ¾à¹° Á¦Á¦ ¹× »õ·Î¿î ¾à¹°Àü´Þ ±â¼úÀ» dz¼± ±â±â¿¡ ÅëÇÕÇÔÀ¸·Î½á Ä¡·á °á°ú¸¦ °³¼±Çϰí Àû¿ë ¹üÀ§¸¦ È®´ëÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù. ƯÈ÷ ½ÅÈï ±¹°¡¿¡¼´Â ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, »õ·Î¿î ½ÃÀå ±âȸ âÃâÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±âȸ¸¦ Ȱ¿ëÇÏ°í ½ÃÀå ÁÖµµ±ÇÀ» À¯ÁöÇϱâ À§Çؼ´Â Àü·«Àû Á¦ÈÞ, R&D ÅõÀÚ, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç µµÀÔÀÌ ÇʼöÀûÀÔ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
´Ù¾çÇÑ ÀÇ·á ÇöÀå¿¡¼ ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼±ÀÇ Ã¤ÅÃÀ» ÃËÁøÇÏ´Â ¾à¹° ó¹æ ¹× ¿ëµµ´Â?
±â¼úÀÇ ¹ßÀüÀº ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô º¯È½Ã۰í Àִ°¡?
¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷Àº ¾îµð¿¡ ÀÖÀ¸¸ç, ½ÃÀå °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» äÅÃÇϰí Àִ°¡?
¼¼°è ¸»ÃÊ¿ë ¾àÁ¦¿ëÃâ dz¼± ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀå ¹üÀ§/ ºÐ·ù
½ÃÀåÀÇ Á¤ÀÇ/ ¹üÀ§/ Á¦ÇÑ
Æ÷ÇÔ°ú Á¦¿Ü
Á¦3Àå ÁÖ¿ä ½ÃÀå µ¿Çâ
½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä µ¿Çâ
¾àÁ¦ ÄÚÆÃ Çõ½Å/°³¹ß µ¿Çâ
Á¦4Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
Áö¿ªº° Á¦Ç° äÅÃ/»ç¿ë »óȲ ºÐ¼®
±ÔÁ¦ ½Ã³ª¸®¿À
±â¼ú Æò°¡
¹ë·ùüÀÎ ºÐ¼®
ÃÖ±Ù Á¦Ç° ½ÂÀΰú ¹ß¸Å
Porter's Five Forces ºÐ¼®
Á¦Ç° USP ºÐ¼®
Á¦5Àå ½ÃÀå ¹è°æ
°Å½Ã°æÁ¦ ¿äÀÎ
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
½ÃÀå ¿ªÇÐ
Á¦6Àå COVID-19 À§±â ºÐ¼®
COVID-19·Î ¿µÇ⠺м®
¾àÁ¦ ÄÚÆÃº°
Áõ»óº°
µ¿¸Æ À¯Çüº°
ÃÖÁ¾»ç¿ëÀÚº°
Áö¿ªº°
2024³â ½ÃÀå ½Ã³ª¸®¿À
Á¦7Àå ¼¼°è ½ÃÀå ¼ö¿ä ¼ö·® ºÐ¼®
°ú°Å ½ÃÀå ¼ö·® ºÐ¼®(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ¼ö·® ¿¹Ãø(2024-2033³â)
Á¦8Àå ¼¼°è ½ÃÀå - °¡°Ý ºÐ¼®
¾àÁ¦ ÄÚÆÃº° Áö¿ª °¡°Ý ºÐ¼®
°¡°Ý ³»¿ª
Á¦Á¶¾÷ü ·¹º§ °¡°Ý°áÁ¤
µð½ºÆ®¸®ºäÅÍ ·¹º§ °¡°Ý°áÁ¤
¼¼°è Æò±Õ °¡°Ý ºÐ¼® º¥Ä¡¸¶Å©
°¡°Ý°áÁ¤ ÀüÁ¦
Á¦9Àå ¼¼°è ½ÃÀå ¼ö¿ä(±Ý¾×) ºÐ¼®
°ú°Å ½ÃÀå ±Ý¾× ºÐ¼®(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ý¾× ¿¹Ãø(2024-2033³â)
Àü³â´ëºñ ¼ºÀå µ¿Ç⠺м®
Àý´ëÀû ÀÌÀÍ ±âȸ ºÐ¼®
¸ÅÃâ ±âȸ ½Ã³ª¸®¿À
Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼® : ¾àÁ¦ ÄÚÆÃº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼® : ¾àÁ¦ ÄÚÆÃº°(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼®¡¤¿¹Ãø : ¾àÁ¦ ÄÚÆÃº°(2024-2033³â)
Paclitaxel ¾àÁ¦ ÄÚÆÃ
Sirolimus ¾àÁ¦ ÄÚÆÃ
±âŸ
¾àÁ¦ ÄÚÆÃ ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦11Àå ¼¼°è ½ÃÀå ºÐ¼® : Áõ»óº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼® : Áõ»óº°(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼®¡¤¿¹Ãø : Áõ»óº°(2024-2033³â)
¸»ÃÊ µ¿¸Æ Áúȯ
¸»ÃÊ µ¿¸Æ·ù
½ºÅÙÆ®³» ÀçÇùÂø
±âŸ
Áõ»ó ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦12Àå ¼¼°è ½ÃÀå ºÐ¼® : µ¿¸Æ À¯Çüº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼® : µ¿¸Æ À¯Çüº°(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼®¡¤¿¹Ãø : µ¿¸Æ À¯Çüº°(2024-2033³â)
°æµ¿¸Æ
Fem-Pop µ¿¸Æ
Àå°ñ µ¿¸Æ
Infrapop µ¿¸Æ
µ¿¸Æ À¯Çüº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦13Àå ¼¼°è ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼®¡¤¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°(2024-2033³â)
º´¿ø
¿Ü·¡ ¼ö¼ú ¼¾ÅÍ/¿Ü·¡ ȯÀÚ
½ÉÀå Ä«Å×ÅÍ °Ë»ç½Ç
ÃÖÁ¾»ç¿ëÀÚº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦14Àå ¼¼°è ½ÃÀå ºÐ¼® : Áö¿ªº°
¼·Ð
°ú°Å ½ÃÀå ±Ô¸ð¡¤¼ö·® ºÐ¼® : Áö¿ªº°(2019-2023³â)
ÇöÀ硤ÇâÈÄ ½ÃÀå ±Ý¾×¡¤¼ö·® ºÐ¼®¡¤¿¹Ãø : Áö¿ªº°(2024-2033³â)
ºÏ¹Ì
¶óƾ¾Æ¸Þ¸®Ä«
À¯·´
³²¾Æ½Ã¾Æ
µ¿¾Æ½Ã¾Æ
¿À¼¼¾Æ´Ï¾Æ
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Áö¿ªº° ½ÃÀåÀÇ ¸Å·Â ºÐ¼®
Á¦15Àå ºÏ¹Ì ½ÃÀå ºÐ¼®
Á¦16Àå ¶óÆ¾¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®
Á¦17Àå À¯·´ ½ÃÀå ºÐ¼®
Á¦18Àå µ¿¾Æ½Ã¾Æ ½ÃÀå ºÐ¼®
Á¦19Àå ³²¾Æ½Ã¾Æ ½ÃÀå ºÐ¼®
Á¦20Àå ¿À¼¼¾Æ´Ï¾Æ ½ÃÀå
Á¦21Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®
Á¦22Àå ½ÃÀå ±¸Á¶ ºÐ¼®
±â¾÷ °èÃþº° ½ÃÀå ºÐ¼®
ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
½ÃÀå ÀÔÁö ºÐ¼®
Á¦23Àå °æÀï ºÐ¼®
°æÀï ´ë½Ãº¸µå
Á¦Á¶¾÷ü¿¡ ÀÇÇÑ ºê·£µù°ú ÇÁ·Î¸ð¼Ç Àü·«
ÁÖ¿ä °³¹ß ºÐ¼®
°æÀï »ó¼¼
Abbott Laboratories
Boston Scientific Corporation
Cook Medical Inc.
MicroPort Scientific Corporation(Endovastec(TM))
Medtronic Plc.
Cardinal Health, Inc.
B. Braun Melsungen AG
BIOTRONIK SE &Co. KG
Becton, Dickinson and Company
WL Gore &Associates Inc.
Getinge AB
Terumo Corp
Kyoto Medical Planning Co Ltd
iVascular SLU
AMG International GmbH
ENDOCOR GmbH
Meril Life Sciences Pvt. Ltd.
Nano Therapeutics Pvt Ltd
Koninklijke Philips NV
REVA Medical
Á¦24Àå »ç¿ëµÇ´Â ÀüÁ¦ Á¶°Ç°ú µÎÀÚ¾î
Á¦25Àå Á¶»ç ¹æ¹ý
KSA
Persistence Market Research has recently released a comprehensive report on the worldwide market for peripheral drug eluting balloons. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
Peripheral Drug Eluting Balloons Market Size (2024E): USD 948.6Million
Projected Market Value (2033F): USD 1950.5 Million
Global Market Growth Rate (CAGR 2024 to 2033): 8.3%
Peripheral Drug Eluting Balloons Market - Report Scope:
Peripheral drug eluting balloons play a crucial role in the treatment of peripheral artery disease (PAD) by delivering medication directly to the arterial walls to inhibit restenosis and improve blood flow. These balloons are used in various healthcare settings, including hospitals, clinics, and outpatient centers, offering a range of drug formulations and balloon sizes to cater to different patient needs. Market growth is driven by the increasing prevalence of PAD, advancements in balloon technology, and a growing preference for minimally invasive procedures.
Market Growth Drivers:
The global peripheral drug eluting balloons market is propelled by several key factors, including the rising incidence of PAD, which affects millions of people worldwide. The demand for effective treatment options that offer sustained drug delivery and reduced restenosis rates is driving the adoption of drug eluting balloons. Technological advancements, such as the development of next-generation balloons with improved drug coatings and delivery mechanisms, enhance treatment efficacy and patient outcomes. Additionally, the increasing adoption of minimally invasive procedures and favorable reimbursement policies are further contributing to market growth.
Market Restraints:
Despite promising growth prospects, the peripheral drug eluting balloons market faces challenges related to regulatory compliance, high costs, and limited awareness in emerging markets. Stringent regulations governing the approval and use of drug eluting balloons impose significant compliance burdens on manufacturers. The high cost of these devices and associated procedures can also be a barrier to widespread adoption, particularly in regions with limited healthcare budgets. Furthermore, the lack of awareness about PAD and available treatment options in developing countries hinders market penetration.
Market Opportunities:
The peripheral drug eluting balloons market presents significant growth opportunities driven by technological innovations, demographic trends, and expanding healthcare infrastructure. The integration of advanced drug formulations and novel delivery technologies into balloon devices is expected to enhance therapeutic outcomes and broaden the application scope. Increasing investments in healthcare infrastructure, particularly in emerging economies, are anticipated to create new market opportunities. Strategic collaborations, investment in R&D, and the introduction of cost-effective solutions are essential to capitalize on these opportunities and sustain market leadership.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the peripheral drug eluting balloons market globally?
Which drug formulations and applications are driving the adoption of peripheral drug eluting balloons across different healthcare settings?
How are technological advancements reshaping the competitive landscape of the peripheral drug eluting balloons market?
Who are the key players contributing to the peripheral drug eluting balloons market, and what strategies are they employing to maintain market relevance?
What are the emerging trends and future prospects in the global peripheral drug eluting balloons market?
Competitive Intelligence and Business Strategy:
Leading players in the global peripheral drug eluting balloons market, including Medtronic, B. Braun Melsungen AG, and Boston Scientific Corporation, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced drug eluting balloon solutions, including devices with enhanced drug coatings and delivery systems, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving peripheral drug eluting balloons landscape.
Key Companies Profiled:
Abbott Laboratories
Boston Scientific Corporation
Cook Medical Inc.
MicroPort Scientific Corporation (Endovastec(TM))
Medtronic Plc.
Cardinal Health, Inc.
B. Braun Melsungen AG
BIOTRONIK SE & Co. KG
Becton, Dickinson and Company
W. L. Gore & Associates Inc.
Getinge AB
Terumo Corp
Kyoto Medical Planning Co Ltd
iVascular S.L.U
AMG International GmbH
ENDOCOR GmbH
Meril Life Sciences Pvt. Ltd.
Nano Therapeutics Pvt Ltd
Koninklijke Philips N.V.
REVA Medical
Key Segments of Peripheral Drug Eluting Balloons Industry Research
Drug Coating:
Paclitaxel Drug Coating
Sirolimus drug Coating
Indication:
Peripheral Arterial Disease
Peripheral Aneurysms
In-Stent Restenosis
Artery Type:
Carotid Arteries
Fem-Pop Arteries
Iliac Arteries
Infrapop Arteries
End User:
Hospitals
Ambulatory Surgical Centers/Outpatients
Cardiac Catheterization Labs
Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Table of Contents
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Drug Coating Innovation / Development Trends
4. Value Added Insights
4.1. Product Adoption/ Usage Analysis, by region
4.2. Regulatory Scenario
4.3. Technology Assessment
4.4. Value Chain Analysis
4.5. Recent Product Approvals and Launches
4.6. Porter's Analysis
4.7. Product USP Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Peripheral Vascular Devices Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growth in Healthcare Spending
5.2.2. Growth in Geriatric Population
5.2.3. Rising Number of Peripheral Surgeries
5.2.4. Technological Advancements
5.2.5. Regulatory Landscape
5.2.6. Cost of Procedures
5.2.7. Product Adoption Rate and Demand
5.2.8. Increase in Research and Development
5.2.9. Pharmaceutical Industry Consolidation Activities
5.2.10. Top Companies' Historical Growth
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Drug Coating
6.1.2. By Indication
6.1.3. By Artery Type
6.1.4. By End User
6.1.5. By Region
6.2. 2024 Market Scenario
7. Global Market Demand in Volume (Units) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Volume (Units) Analysis, 2019-2023
7.2. Current and Future Market Volume (Units) (Units) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis By Drug Coating
8.2. Pricing Break-up
8.2.1. Manufacturer Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
8.4. Pricing Assumptions
9. Global Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033
9.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
9.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
9.3. Revenue Opportunity Scenario
10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Coating
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Drug Coating, 2019-2023
10.3. Current and Future Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, by Drug Coating, 2024-2033
10.3.1. Paclitaxel Drug Coating
10.3.2. Sirolimus drug Coating
10.3.3. Others
10.4. Market Attractiveness Analysis, by Drug Coating
11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Indication
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis, By Indication, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Indication, 2024-2033
11.3.1. Peripheral Arterial Disease
11.3.2. Peripheral Aneurysms
11.3.3. In-Stent Restenosis
11.3.4. Others
11.4. Market Attractiveness Analysis, by Indication
12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Artery Type
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis, By Artery Type, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by Artery Type, 2024-2033
12.3.1. Carotid Artery
12.3.2. Fem-Pop Artery
12.3.3. Iliac Artery
12.3.4. Infrapop Artery
12.4. Market Attractiveness Analysis, by Artery Type
13. Global Market Analysis 2019-2023 and Forecast 2024-2033, By End User
13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, by End User, 2024-2033
13.3.1. Hospitals
13.3.2. Ambulatory Surgical Centers/Outpatients
13.3.3. Cardiac Catheterization Labs
13.4. Market Attractiveness Analysis, by End User
14. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region
14.1. Introduction
14.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Region, 2019-2023
14.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, By Region, 2024-2033
14.3.1. North America
14.3.2. Latin America
14.3.3. Europe
14.3.4. South Asia
14.3.5. East Asia
14.3.6. Oceania
14.3.7. Middle East and Africa (MEA)
14.4. Market Attractiveness Analysis, by Region
15. North America Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. U.S.
15.3.1.2. Canada
15.3.2. By Drug Coating
15.3.3. By Indication
15.3.4. By Artery Type
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Coating
15.4.3. By Indication
15.4.4. By Artery Type
15.4.5. By End User
15.5. PESTLE Analysis
15.6. Market Trends
15.7. Key Market Participants - Intensity Mapping
15.8. Drivers and Restraints - Impact Analysis
15.9. Country Level Analysis & Forecast
15.9.1. U.S. Market Analysis
15.9.1.1. Introduction
15.9.1.2. Market Analysis and Forecast, by Market Taxonomy
15.9.1.2.1. By Drug Coating
15.9.1.2.2. By Indication
15.9.1.2.3. By Artery Type
15.9.1.2.4. By End User
15.9.2. Canada Market Analysis
15.9.2.1. Introduction
15.9.2.2. Market Analysis and Forecast, by Market Taxonomy
15.9.2.2.1. By Drug Coating
15.9.2.2.2. By Indication
15.9.2.2.3. By Artery Type
15.9.2.2.4. By End User
16. Latin America Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. Mexico
16.3.1.2. Brazil
16.3.1.3. Argentina
16.3.1.4. Rest of Latin America
16.3.2. By Drug Coating
16.3.3. By Indication
16.3.4. By Artery Type
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Coating
16.4.3. By Indication
16.4.4. By Artery Type
16.4.5. By End User
16.5. PESTLE Analysis
16.6. Market Trends
16.7. Key Market Participants - Intensity Mapping
16.8. Drivers and Restraints - Impact Analysis
16.9. Country Level Analysis & Forecast
16.9.1. Mexico Market Analysis
16.9.1.1. Introduction
16.9.1.2. Market Analysis and Forecast, by Market Taxonomy
16.9.1.2.1. By Drug Coating
16.9.1.2.2. By Indication
16.9.1.2.3. By Artery Type
16.9.1.2.4. By End User
16.9.2. Brazil Market Analysis
16.9.2.1. Introduction
16.9.2.2. Market Analysis and Forecast, by Market Taxonomy
16.9.2.2.1. By Drug Coating
16.9.2.2.2. By Indication
16.9.2.2.3. By Artery Type
16.9.2.2.4. By End User
16.9.3. Argentina Market Analysis
16.9.3.1. Introduction
16.9.3.2. Market Analysis and Forecast, by Market Taxonomy
16.9.3.2.1. By Drug Coating
16.9.3.2.2. By Indication
16.9.3.2.3. By Artery Type
16.9.3.2.4. By End User
17. Europe Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. Germany
17.3.1.2. Italy
17.3.1.3. France
17.3.1.4. U.K.
17.3.1.5. Spain
17.3.1.6. BENELUX
17.3.1.7. Russia
17.3.1.8. Nordic Countries
17.3.1.9. Rest of Europe
17.3.2. By Drug Coating
17.3.3. By Indication
17.3.4. By Artery Type
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Coating
17.4.3. By Indication
17.4.4. By Artery Type
17.4.5. By End User
17.5. PESTLE Analysis
17.6. Market Trends
17.7. Key Market Participants - Intensity Mapping
17.8. Drivers and Restraints - Impact Analysis
17.9. Country Level Analysis & Forecast
17.9.1. Germany Market Analysis
17.9.1.1. Introduction
17.9.1.2. Market Analysis and Forecast, by Market Taxonomy
17.9.1.2.1. By Drug Coating
17.9.1.2.2. By Indication
17.9.1.2.3. By Artery Type
17.9.1.2.4. By End User
17.9.2. Italy Market Analysis
17.9.2.1. Introduction
17.9.2.2. Market Analysis and Forecast, by Market Taxonomy
17.9.2.2.1. By Drug Coating
17.9.2.2.2. By Indication
17.9.2.2.3. By Artery Type
17.9.2.2.4. By End User
17.9.3. France Market Analysis
17.9.3.1. Introduction
17.9.3.2. Market Analysis and Forecast, by Market Taxonomy
17.9.3.2.1. By Drug Coating
17.9.3.2.2. By Indication
17.9.3.2.3. By Artery Type
17.9.3.2.4. By End User
17.9.4. U.K. Market Analysis
17.9.4.1. Introduction
17.9.4.2. Market Analysis and Forecast, by Market Taxonomy
17.9.4.2.1. By Drug Coating
17.9.4.2.2. By Indication
17.9.4.2.3. By Artery Type
17.9.4.2.4. By End User
17.9.5. Spain Market Analysis
17.9.5.1. Introduction
17.9.5.2. Market Analysis and Forecast, by Market Taxonomy
17.9.5.2.1. By Drug Coating
17.9.5.2.2. By Indication
17.9.5.2.3. By Artery Type
17.9.5.2.4. By End User
17.9.6. BENELUX Market Analysis
17.9.6.1. Introduction
17.9.6.2. Market Analysis and Forecast, by Market Taxonomy
17.9.6.2.1. By Drug Coating
17.9.6.2.2. By Indication
17.9.6.2.3. By Artery Type
17.9.6.2.4. By End User
17.9.7. Russia Market Analysis
17.9.7.1. Introduction
17.9.7.2. Market Analysis and Forecast, by Market Taxonomy
17.9.7.2.1. By Drug Coating
17.9.7.2.2. By Indication
17.9.7.2.3. By Artery Type
17.9.7.2.4. By End User
17.9.8. Nordic Countries Market Analysis
17.9.8.1. Introduction
17.9.8.2. Market Analysis and Forecast, by Market Taxonomy
17.9.8.2.1. By Drug Coating
17.9.8.2.2. By Indication
17.9.8.2.3. By Artery Type
17.9.8.2.4. By End User
18. East Asia Market Analysis 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market End User (US$ Mn) Analysis, by Market Taxonomy, 2019-2023
18.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. China
18.3.1.2. Japan
18.3.1.3. South Korea
18.3.2. By Drug Coating
18.3.3. By Indication
18.3.4. By Artery Type
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Drug Coating
18.4.3. By Indication
18.4.4. By Artery Type
18.4.5. By End User
18.5. PESTLE Analysis
18.6. Market Trends
18.7. Key Market Participants - Intensity Mapping
18.8. Drivers and Restraints - Impact Analysis
18.9. Country Level Analysis & Forecast
18.9.1. China Market Analysis
18.9.1.1. Introduction
18.9.1.2. Market Analysis and Forecast, by Market Taxonomy
18.9.1.2.1. By Drug Coating
18.9.1.2.2. By Indication
18.9.1.2.3. By Artery Type
18.9.1.2.4. By End User
18.9.2. Japan Market Analysis
18.9.2.1. Introduction
18.9.2.2. Market Analysis and Forecast, by Market Taxonomy
18.9.2.2.1. By Drug Coating
18.9.2.2.2. By Indication
18.9.2.2.3. By Artery Type
18.9.2.2.4. By End User
18.9.3. South Korea Market Analysis
18.9.3.1. Introduction
18.9.3.2. Market Analysis and Forecast, by Market Taxonomy
18.9.3.2.1. By Drug Coating
18.9.3.2.2. By Indication
18.9.3.2.3. By Artery Type
18.9.3.2.4. By End User
19. South Asia Market Analysis 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
19.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
19.3.1. By Country
19.3.1.1. India
19.3.1.2. Indonesia
19.3.1.3. Malaysia
19.3.1.4. Thailand
19.3.1.5. Rest of South Asia
19.3.2. By Drug Coating
19.3.3. By Indication
19.3.4. By Artery Type
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Drug Coating
19.4.3. By Indication
19.4.4. By Artery Type
19.4.5. By End User
19.5. PESTLE Analysis
19.6. Market Trends
19.7. Key Market Participants - Intensity Mapping
19.8. Drivers and Restraints - Impact Analysis
19.9. Country Level Analysis & Forecast
19.9.1. India Market Analysis
19.9.1.1. Introduction
19.9.1.2. Market Analysis and Forecast, by Market Taxonomy
19.9.1.2.1. By Drug Coating
19.9.1.2.2. By Indication
19.9.1.2.3. By Artery Type
19.9.1.2.4. By End User
19.9.2. Indonesia Market Analysis
19.9.2.1. Introduction
19.9.2.2. Market Analysis and Forecast, by Market Taxonomy
19.9.2.2.1. By Drug Coating
19.9.2.2.2. By Indication
19.9.2.2.3. By Artery Type
19.9.2.2.4. By End User
19.9.3. Malaysia Market Analysis
19.9.3.1. Introduction
19.9.3.2. Market Analysis and Forecast, by Market Taxonomy
19.9.3.2.1. By Drug Coating
19.9.3.2.2. By Indication
19.9.3.2.3. By Artery Type
19.9.3.2.4. By End User
19.9.4. Thailand Market Analysis
19.9.4.1. Introduction
19.9.4.2. Market Analysis and Forecast, by Market Taxonomy
19.9.4.2.1. By Drug Coating
19.9.4.2.2. By Indication
19.9.4.2.3. By Artery Type
19.9.4.2.4. By End User
20. Oceania Market 2019-2023 and Forecast 2024-2033
20.1. Introduction
20.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
20.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
20.3.1. By Country
20.3.1.1. Australia
20.3.1.2. New Zealand
20.3.2. By Drug Coating
20.3.3. By Indication
20.3.4. By Artery Type
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Drug Coating
20.4.3. By Indication
20.4.4. By Artery Type
20.4.5. By End User
20.5. PESTLE Analysis
20.6. Market Trends
20.7. Key Market Participants - Intensity Mapping
20.8. Drivers and Restraints - Impact Analysis
20.9. Country Level Analysis & Forecast
20.9.1. Australia Market Analysis
20.9.1.1. Introduction
20.9.1.2. Market Analysis and Forecast, by Market Taxonomy
20.9.1.2.1. By Drug Coating
20.9.1.2.2. By Indication
20.9.1.2.3. By Artery Type
20.9.1.2.4. By End User
20.9.2. New Zealand Market Analysis
20.9.2.1. Introduction
20.9.2.2. Market Analysis and Forecast, by Market Taxonomy
20.9.2.2.1. By Drug Coating
20.9.2.2.2. By Indication
20.9.2.2.3. By Artery Type
20.9.2.2.4. By End User
21. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033
21.1. Introduction
21.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, by Market Taxonomy, 2019-2023
21.3. Current and Future Market Value (US$ Mn) Volume (Units) Analysis and Forecast, by Market Taxonomy, 2024-2033
21.3.1. By Country
21.3.1.1. GCC Countries
21.3.1.2. Turkey
21.3.1.3. Israel
21.3.1.4. South Africa
21.3.1.5. North Africa
21.3.1.6. Rest of Middle East and Africa
21.3.2. By Drug Coating
21.3.3. By Indication
21.3.4. By Artery Type
21.3.5. By End User
21.4. Market Attractiveness Analysis
21.4.1. By Country
21.4.2. By Drug Coating
21.4.3. By Indication
21.4.4. By Artery Type
21.4.5. By End User
21.5. PESTLE Analysis
21.6. Market Trends
21.7. Key Market Participants - Intensity Mapping
21.8. Drivers and Restraints - Impact Analysis
21.9. Country Level Analysis & Forecast
21.9.1. GCC Countries Market Analysis
21.9.1.1. Introduction
21.9.1.2. Market Analysis and Forecast, by Market Taxonomy
21.9.1.2.1. By Drug Coating
21.9.1.2.2. By Indication
21.9.1.2.3. By Artery Type
21.9.1.2.4. By End User
21.9.2. Turkey Market Analysis
21.9.2.1. Introduction
21.9.2.2. Market Analysis and Forecast, by Market Taxonomy
21.9.2.2.1. By Drug Coating
21.9.2.2.2. By Indication
21.9.2.2.3. By Artery Type
21.9.2.2.4. By End User
21.9.3. Israel Africa Market Analysis
21.9.3.1. Introduction
21.9.3.2. Market Analysis and Forecast, by Market Taxonomy
21.9.3.2.1. By Drug Coating
21.9.3.2.2. By Indication
21.9.3.2.3. By Artery Type
21.9.3.2.4. By End User
21.9.4. South Africa Market Analysis
21.9.4.1. Introduction
21.9.4.2. Market Analysis and Forecast, by Market Taxonomy
21.9.4.2.1. By Drug Coating
21.9.4.2.2. By Indication
21.9.4.2.3. By Artery Type
21.9.4.2.4. By End User
21.9.5. North Africa Market Analysis
21.9.5.1. Introduction
21.9.5.2. Market Analysis and Forecast, by Market Taxonomy
21.9.5.2.1. By Drug Coating
21.9.5.2.2. By Indication
21.9.5.2.3. By Artery Type
21.9.5.2.4. By End User
22. Market Structure Analysis
22.1. Market Analysis, by Tier of Companies
22.2. Market Share Analysis of Top Players
22.3. Market Presence Analysis
23. Competition Analysis
23.1. Competition Dashboard
23.2. Branding and Promotional Strategies, By Manufacturers
23.3. Key Development Analysis
23.4. Competition Deep Dive
23.4.1. Abbott Laboratories
23.4.1.1. Overview
23.4.1.2. Product Portfolio
23.4.1.3. Sales Footprint
23.4.1.4. Key Financials
23.4.1.5. SWOT Analysis
23.4.1.6. Key Developments
23.4.1.7. Strategy Overview
23.4.1.7.1. Marketing Strategy
23.4.1.7.2. Product Strategy
23.4.1.7.3. Channel Strategy
23.4.2. Boston Scientific Corporation
23.4.2.1. Overview
23.4.2.2. Product Portfolio
23.4.2.3. Sales Footprint
23.4.2.4. Key Financials
23.4.2.5. SWOT Analysis
23.4.2.6. Key Developments
23.4.2.7. Strategy Overview
23.4.2.7.1. Marketing Strategy
23.4.2.7.2. Product Strategy
23.4.2.7.3. Channel Strategy
23.4.3. Cook Medical Inc.
23.4.3.1. Overview
23.4.3.2. Product Portfolio
23.4.3.3. Sales Footprint
23.4.3.4. Key Financials
23.4.3.5. SWOT Analysis
23.4.3.6. Key Developments
23.4.3.7. Strategy Overview
23.4.3.7.1. Marketing Strategy
23.4.3.7.2. Product Strategy
23.4.3.7.3. Channel Strategy
23.4.4. MicroPort Scientific Corporation (Endovastec(TM))
23.4.4.1. Overview
23.4.4.2. Product Portfolio
23.4.4.3. Sales Footprint
23.4.4.4. Key Financials
23.4.4.5. SWOT Analysis
23.4.4.6. Key Developments
23.4.4.7. Strategy Overview
23.4.4.7.1. Marketing Strategy
23.4.4.7.2. Product Strategy
23.4.4.7.3. Channel Strategy
23.4.5. Medtronic Plc.
23.4.5.1. Overview
23.4.5.2. Product Portfolio
23.4.5.3. Sales Footprint
23.4.5.4. Key Financials
23.4.5.5. SWOT Analysis
23.4.5.6. Key Developments
23.4.5.7. Strategy Overview
23.4.5.7.1. Marketing Strategy
23.4.5.7.2. Product Strategy
23.4.5.7.3. Channel Strategy
23.4.6. Cardinal Health, Inc.
23.4.6.1. Overview
23.4.6.2. Product Portfolio
23.4.6.3. Sales Footprint
23.4.6.4. Key Financials
23.4.6.5. SWOT Analysis
23.4.6.6. Key Developments
23.4.6.7. Strategy Overview
23.4.6.7.1. Marketing Strategy
23.4.6.7.2. Product Strategy
23.4.6.7.3. Channel Strategy
23.4.7. B. Braun Melsungen AG
23.4.7.1. Overview
23.4.7.2. Product Portfolio
23.4.7.3. Sales Footprint
23.4.7.4. Key Financials
23.4.7.5. SWOT Analysis
23.4.7.6. Key Developments
23.4.7.7. Strategy Overview
23.4.7.7.1. Marketing Strategy
23.4.7.7.2. Product Strategy
23.4.7.7.3. Channel Strategy
23.4.8. BIOTRONIK SE & Co. KG
23.4.8.1. Overview
23.4.8.2. Product Portfolio
23.4.8.3. Sales Footprint
23.4.8.4. Key Financials
23.4.8.5. SWOT Analysis
23.4.8.6. Key Developments
23.4.8.7. Strategy Overview
23.4.8.7.1. Marketing Strategy
23.4.8.7.2. Product Strategy
23.4.8.7.3. Channel Strategy
23.4.9. Becton, Dickinson and Company
23.4.9.1. Overview
23.4.9.2. Product Portfolio
23.4.9.3. Sales Footprint
23.4.9.4. Key Financials
23.4.9.5. SWOT Analysis
23.4.9.6. Key Developments
23.4.9.7. Strategy Overview
23.4.9.7.1. Marketing Strategy
23.4.9.7.2. Product Strategy
23.4.9.7.3. Channel Strategy
23.4.10. W. L. Gore & Associates Inc.
23.4.10.1. Overview
23.4.10.2. Product Portfolio
23.4.10.3. Sales Footprint
23.4.10.4. Key Financials
23.4.10.5. SWOT Analysis
23.4.10.6. Key Developments
23.4.10.7. Strategy Overview
23.4.10.7.1. Marketing Strategy
23.4.10.7.2. Product Strategy
23.4.10.7.3. Channel Strategy
23.4.11. Getinge AB
23.4.11.1. Overview
23.4.11.2. Product Portfolio
23.4.11.3. Sales Footprint
23.4.11.4. Key Financials
23.4.11.5. SWOT Analysis
23.4.11.6. Key Developments
23.4.11.7. Strategy Overview
23.4.11.7.1. Marketing Strategy
23.4.11.7.2. Product Strategy
23.4.11.7.3. Channel Strategy
23.4.12. Terumo Corp
23.4.12.1. Overview
23.4.12.2. Product Portfolio
23.4.12.3. Sales Footprint
23.4.12.4. Key Financials
23.4.12.5. SWOT Analysis
23.4.12.6. Key Developments
23.4.12.7. Strategy Overview
23.4.12.7.1. Marketing Strategy
23.4.12.7.2. Product Strategy
23.4.12.7.3. Channel Strategy
23.4.13. Kyoto Medical Planning Co Ltd
23.4.13.1. Overview
23.4.13.2. Product Portfolio
23.4.13.3. Sales Footprint
23.4.13.4. Key Financials
23.4.13.5. SWOT Analysis
23.4.13.6. Key Developments
23.4.13.7. Strategy Overview
23.4.13.7.1. Marketing Strategy
23.4.13.7.2. Product Strategy
23.4.13.7.3. Channel Strategy
23.4.14. iVascular S.L.U
23.4.14.1. Overview
23.4.14.2. Product Portfolio
23.4.14.3. Sales Footprint
23.4.14.4. Key Financials
23.4.14.5. SWOT Analysis
23.4.14.6. Key Developments
23.4.14.7. Strategy Overview
23.4.14.7.1. Marketing Strategy
23.4.14.7.2. Product Strategy
23.4.14.7.3. Channel Strategy
23.4.15. AMG International GmbH
23.4.15.1. Overview
23.4.15.2. Product Portfolio
23.4.15.3. Sales Footprint
23.4.15.4. Key Financials
23.4.15.5. SWOT Analysis
23.4.15.6. Key Developments
23.4.15.7. Strategy Overview
23.4.15.7.1. Marketing Strategy
23.4.15.7.2. Product Strategy
23.4.15.7.3. Channel Strategy
23.4.16. ENDOCOR GmbH
23.4.16.1. Overview
23.4.16.2. Product Portfolio
23.4.16.3. Sales Footprint
23.4.16.4. Key Financials
23.4.16.5. SWOT Analysis
23.4.16.6. Key Developments
23.4.16.7. Strategy Overview
23.4.16.7.1. Marketing Strategy
23.4.16.7.2. Product Strategy
23.4.16.7.3. Channel Strategy
23.4.17. Meril Life Sciences Pvt. Ltd.
23.4.17.1. Overview
23.4.17.2. Product Portfolio
23.4.17.3. Sales Footprint
23.4.17.4. Key Financials
23.4.17.5. SWOT Analysis
23.4.17.6. Key Developments
23.4.17.7. Strategy Overview
23.4.17.7.1. Marketing Strategy
23.4.17.7.2. Product Strategy
23.4.17.7.3. Channel Strategy
23.4.18. Nano Therapeutics Pvt Ltd
23.4.18.1. Overview
23.4.18.2. Product Portfolio
23.4.18.3. Sales Footprint
23.4.18.4. Key Financials
23.4.18.5. SWOT Analysis
23.4.18.6. Key Developments
23.4.18.7. Strategy Overview
23.4.18.7.1. Marketing Strategy
23.4.18.7.2. Product Strategy
23.4.18.7.3. Channel Strategy
23.4.19. Koninklijke Philips N.V.
23.4.19.1. Overview
23.4.19.2. Product Portfolio
23.4.19.3. Sales Footprint
23.4.19.4. Key Financials
23.4.19.5. SWOT Analysis
23.4.19.6. Key Developments
23.4.19.7. Strategy Overview
23.4.19.7.1. Marketing Strategy
23.4.19.7.2. Product Strategy
23.4.19.7.3. Channel Strategy
23.4.20. REVA Medical
23.4.20.1. Overview
23.4.20.2. Product Portfolio
23.4.20.3. Sales Footprint
23.4.20.4. Key Financials
23.4.20.5. SWOT Analysis
23.4.20.6. Key Developments
23.4.20.7. Strategy Overview
23.4.20.7.1. Marketing Strategy
23.4.20.7.2. Product Strategy
23.4.20.7.3. Channel Strategy
24. Assumptions and Acronyms Used
25. Research Methodology